Beyond The Numbers: 6 Analysts Discuss Axogen Stock
Benzinga Insights 8 months ago
Analyst Ratings
Analysts' ratings for Axogen (NASDAQ:AXGN) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 4 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.67, along with a high estimate of $40.00 and a low estimate of $36.00. Surpassing the previous average price target of $28.00, the current average has increased by 38.11%.
Analyzing Analyst Ratings: A Detailed Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Axogen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Larry Biegelsen | Wells Fargo | Announces | Overweight | $40.00 | - |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $37.00 | $27.00 |
| Yi Chen | HC Wainwright & Co. | Raises | Buy | $39.00 | $26.00 |
| Michael Sarcone | Jefferies | Raises | Buy | $36.00 | $29.00 |
| Frank Takkinen | Lake Street | Raises | Buy | $40.00 | $30.00 |
| Anthony Petrone | Mizuho | Announces | Outperform | $40.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axogen. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Axogen compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Axogen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Axogen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Axogen analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Axogen's Background
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Financial Insights: Axogen
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Axogen's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 23.51%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Axogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Axogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.61% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Axogen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.56, Axogen adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.